Compare JBGS & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBGS | ARDX |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.7M | 975.9M |
| IPO Year | 2017 | 2014 |
| Metric | JBGS | ARDX |
|---|---|---|
| Price | $10.53 | $3.42 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $15.00 | ★ $15.14 |
| AVG Volume (30 Days) | 801.0K | ★ 3.9M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $498,598,000.00 | $2,607,000.00 |
| Revenue This Year | N/A | $37.75 |
| Revenue Next Year | N/A | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.41 | $3.33 |
| 52 Week High | $22.38 | $8.40 |
| Indicator | JBGS | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 30.51 | 33.22 |
| Support Level | N/A | $3.33 |
| Resistance Level | $11.55 | $3.92 |
| Average True Range (ATR) | 0.33 | 0.13 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 17.02 | 18.80 |
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.